Exelixis (EXEL) reported Q1 non-GAAP net income late Tuesday of $0.62 per diluted share, up from $0.17 a year earlier.
Analysts polled by FactSet expected $0.44.
Revenue for the quarter ended March 31 was $555.4 million, up from $425.2 million a year earlier.
Analysts polled by FactSet expected $499.6 million.
For full-year 2025, the oncology company increased its revenue guidance to a range of $2.25 billion to $2.35 billion, up from its prior outlook of $2.15 billion to $2.25 billion. Analysts polled by FactSet are looking for $2.25 billion.
Exelixis shares were up more than 6% in Tuesday's after-market activity.
Price: 39.35, Change: +2.40, Percent Change: +6.50
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.